MedTrace Logo

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

NCT04380753 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Interventions

DRUG

AMG 510

Subjects will be enrolled and will receive AMG 510 PO QD.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2021-12-31
Completion
2026-02-09
FDA Drug
Yes

Countries

  • Hong Kong
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380753 on ClinicalTrials.gov